This stock started acting sick prior to the
sell-off. I am more concerned with the SEC questioning the
FASB about the potential reversal of the GAAP
concerning excessive write-offs in M&A deals. This has the
potential to do a total revaluation in the way M&A deals
are handled and the premium that merger candidates
recieve. If this ruling passes HIB will see $10/share,
unless they refocus their strategy on efficency instead
of market share. I have not been impressed with
HIB's strategy. Changes must be made or HIB will not
participate when these stocks rally.